Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04794101
Other study ID # MGT-RPGR-022
Secondary ID MGT-RPGR-0222020
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date December 4, 2020
Est. completion date December 19, 2029

Study information

Verified date June 2024
Source Janssen Research & Development, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A clinical trial of AAV5-hRKp.RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 97
Est. completion date December 19, 2029
Est. primary completion date September 20, 2029
Accepts healthy volunteers No
Gender All
Age group 3 Years and older
Eligibility Inclusion Criteria: - Male or female, 3 years of age or older, has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory. Exclusion Criteria: - None

Study Design


Intervention

Biological:
Genetic: AAV5-hRKp.RPGR Intermediate Dose
Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group
Genetic: AAV5-hRKp.RPGR Low Dose
Bilateral, subretinal administration of AAV5-hRKp.RPGR - deferred treatment group

Locations

Country Name City State
Belgium Ghent University Hospital Gent
Canada Hospital For Sick Children Toronto Ontario
Denmark Rigshospitalet Glostrup Glostrup
France Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Paris
Israel Hadassah Medical Center Jerusalem
Italy Azienda Ospedaliero Universitaria Careggi Firenze
Italy Ospedale San Paolo Milano
Italy Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli Napoli
Italy IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS Rome
Netherlands VUMC Amsterdam Amsterdam
Netherlands Radboudumc Nijmegen
Spain Hosp Univ Fund Jimenez Diaz Madrid
Switzerland University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical Basel
Switzerland Universite de Lausanne, Hopital ophtalmique Jules-Gonin Lausanne
United Kingdom NHS Lothian Edinburgh
United Kingdom Gartnavel General Hospital Glasgow
United Kingdom St James University Hospital Leeds
United Kingdom Moorfields Eye Hospital London
United States Univ of Michigan Medical Center Ann Arbor Michigan
United States Emory University Atlanta Georgia
United States Retina Consultants of Houston Bellaire Texas
United States Massachusetts Eye and Ear Infirmary Boston Massachusetts
United States Duke Eye Center Durham North Carolina
United States VitreoRetinal Associates, PA Gainesville Florida
United States Shiley Eye Institute Jacobs Retina Center La Jolla California
United States Childrens Hospital Los Angeles Los Angeles California
United States Stanford Health Care Palo Alto California
United States University of Pittsburgh Medical Center (UPMC) Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Janssen Research & Development, LLC

Countries where clinical trial is conducted

United States,  Belgium,  Canada,  Denmark,  France,  Israel,  Italy,  Netherlands,  Spain,  Switzerland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in vision-guided mobility assessment (VMA), as measured by the ability of the participant to navigate through a VMA maze, after bilateral subretinal delivery of AAV5-hRKp.RPGR Change from baseline in vision-guided mobility assessment (VMA), as measured by the ability of the participant to navigate through a VMA maze, after bilateral subretinal delivery of AAV5-hRKp.RPGR From Baseline to Month 60
Primary Number of participants with Ocular and Non-ocular Adverse Events of AAV5-hRKp.RPGR in Participants with RPGR-XLRP Number of participants with ocular and non-ocular adverse events of AAV5-hRKp.RPGR in participants with RPGR-XLRP will be assessed. Day 1 - Month 60
Primary Number of Participants With Abnormalities in Laboratory Assessments Number of participants with abnormalities in laboratory assessments will be assessed. Day 1 - Month 60
Secondary Change From Baseline in Mean Retinal Sensitivity Within the Central 10 Degrees Excluding Scotoma (MRS10) in Static Perimetry Change from baseline in mean retinal sensitivity within the central 10 degrees excluding scotoma (MRS10) in static perimetry will be assessed. From Baseline to Month 60
Secondary Change From Baseline in Mean Retinal Sensitivity of Worse-seeing Eye Within the Central 10 Degrees Excluding Scotoma (MRS10) in Static Perimetry Change from baseline in mean retinal sensitivity of worse-seeing eye within the central 10 degrees excluding scotoma (MRS10) in static perimetry will be assessed. From Baseline to Month 60
Secondary Change in Retinal Function as Assessed by Pointwise Response in Full Visual Field Pointwise response in full visual field will be assessed. From Baseline to Month 60
Secondary Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in Full Visual Field Pointwise response in worse-seeing eye in full visual field will be assessed. From Baseline to Month 60
Secondary Change in Retinal Function as Assessed by Pointwise Response in the Central 30-degree Visual Field Pointwise response in the central 30-degree visual field will be assessed. From Baseline to Month 60
Secondary Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in the Central 30-degree Visual Field Pointwise response in worse-seeing eye in the central 30-degree visual field will be assessed. From Baseline to Month 60
Secondary Change From Baseline in Mean Retinal Sensitivity Within the Full Visual Field Excluding Scotoma (MRS90) in Static Perimetry Change from baseline in mean retinal sensitivity within the full visual field excluding scotoma (MRS90) in static perimetry will be assessed. From Baseline to Month 60
Secondary Vision-guided Mobility Assessment (VMA) Response in the "Worse-seeing Eye" as Assessed by VMA Vision-guided mobility assessment response in the "worse-seeing eye" as assessed by VMA will be assessed. From Baseline to Month 60
Secondary Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain Score Change from baseline in the mLLQ extreme lighting domain score will be assessed. From Baseline to Month 60
Secondary Change From Baseline in Low Luminance Visual Acuity by Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter Score in Monocular Assessment Change from baseline in low luminance visual acuity by ETDRS chart letter score in monocular assessment will be assessed. From Baseline- Month 60
Secondary Change From Baseline in Best Corrected Visual Acuity (BCVA) by ETDRS Chart Letter Score in Monocular Assessment Change from baseline in BCVA by ETDRS chart letter score in monocular assessment will be assessed. From Baseline - Month 60
Secondary Change From Baseline in Low Luminance Visual Acuity by ETDRS Chart Letter Score in Worse-seeing Eye Change from baseline in low luminance visual acuity by ETDRS chart letter score in worse-seeing eye will be assessed. From Baseline to Month 60
See also
  Status Clinical Trial Phase
Completed NCT04926129 - Natural History of the Progression of X-Linked Retinitis Pigmentosa
Recruiting NCT05926583 - A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa Phase 3
Enrolling by invitation NCT06275620 - A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN) Phase 2
Completed NCT03116113 - A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 Phase 1/Phase 2
Recruiting NCT04850118 - A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP Phase 2/Phase 3
Active, not recruiting NCT04517149 - 4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP) Phase 1/Phase 2
Enrolling by invitation NCT03584165 - Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa Phase 3
Active, not recruiting NCT04312672 - Long-term Follow-up Gene Therapy Study for RPGR- XLRP
Completed NCT04868916 - An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa
Completed NCT03252847 - Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR) Phase 1/Phase 2
Recruiting NCT05874310 - Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa Early Phase 1
Active, not recruiting NCT04671433 - Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene Phase 3
Completed NCT03314207 - Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)
Active, not recruiting NCT03316560 - Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations Phase 1/Phase 2
Active, not recruiting NCT06333249 - A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE) Phase 2